Table 1

Baseline characteristics by group

VariableMethylphenidate
(n=15)
Placebo
(n=7)
Age at randomisation (years)55.5 (10.1)55.4 (7.7)
Gender (%)
 Male10 (66.7)3 (42.9)
 Female5 (33.3)4 (57.1)
Smoking status (%)
 Current0 (0.0)0 (0.0)
 Ex4 (26.7)3 (42.9)
 Never11 (73.3)4 (57.1)
Alcohol intake (units/week)5.3 (7.6)4.7 (10.3)
Body mass index (kg/m2)30.3 (4.5)33.8 (7.6)
Disease duration at randomisation (years)6.7 (7.1)6.0 (7.8)
 >3 years9 (60.0)4 (57.1)
 1–3 years2 (13.3)2 (28.6)
 <1 year4 (26.7)1 (14.3)
Pulmonary disease (%)15 (100.0)7 (100.0)
Extrapulmonary disease (%)9 (60.0)3 (42.9)
Ethnicity
 Caucasian15 (100.0)7 (100.0)
Current treatment for sarcoidosis4 (26.7)4 (57.2)
 Prednisolone3 (20.0)1 (14.3)
 Methotrexate1 (6.7)2 (28.6)
 Azathioprine0 (0.0)1 (14.3)
Baseline FAS Score35.9 (7.7)35.9 (8.8)
 FAS score 21–34 (%)7 (46.7)3 (42.9)
 FAS score 34–50 (%)8 (53.3)4 (57.1)
  • Values presented as means (SD) or frequencies (%).

  • FAS, Fatigue Assessment Scale.